Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: enduring (19), lasting (771), stable (196)

Announcement regarding the UHS chief executive Paula Head

Description: Announcement regarding the UHS chief executive Paula Head
Url: /AboutTheTrust/Newsandpublications/Latestnews/2020/November/Announcement-regarding-the-UHS-chief-executive-Paula-Head.aspx

Council grants planning permission for hospital park and ride and health campus

Description: Test Valley Borough Council has given the green light for a permanent park and ride facility for staff working at UHS
Url: /AboutTheTrust/Newsandpublications/Latestnews/2019/December/Council-grants-planning-permission-for-hospital-park-and-ride-and-health-campus.aspx

Announcement regarding UHS chief executive Fiona Dalton

Description: I am writing to let you know that Fiona Dalton, the UHS chief executive, will be leaving the trust having accepted
Url: /AboutTheTrust/Newsandpublications/Latestnews/2017/December-2017/Announcement-regarding-UHS-chief-executive.aspx

Cemiplimab

Description: Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous s
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

Thalamotomy - patient information

Description: This factsheet explains what a thalamotomy is, what the procedure involves, and what the possible benefits and risks are.
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Thalamotomy-3292-PIL.pdf

Endometrial-Dostarlimab

Description: Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients wi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indicatio
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as a
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Nivolumab ver 1 (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Meta
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

31 to 40 of 201

Previous … 2 3 4 5 6 … Next